KPTI.US Karyopharm Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.0174 USD
Close of Nov 11, 2026
0.0170 10.99
Market cap
USD 395K
P/E
-
P/B
12.05x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is KPTI.US undervalued?

Graham number

The Graham number of Karyopharm Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Karyopharm Therapeutics Inc fundamental analysis

No fundamental analysis for Karyopharm Therapeutics Inc yet.

Karyopharm Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and…

Full company profile